Lauren Lipira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren Lipira has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Emily C. Williams
Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle, WA, United States
3 shared publications - Christopher Galloway Kemp
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
2 shared publications - Lalaine Sevillano
School of Social Work, Portland State University
2 shared publications - Matthew Alan Town
Department of Public Health, Pacific University, Forest Grove, OR, USA
2 shared publications - Sara Nelson Glick
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA
2 shared publications - Timothy William Menza
Division of Allergy and Infectious Diseases, University of Washington , Seattle, WA
2 shared publications
Latest Publications
- Open Access
- 12 March 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Fentanyl use among people who inject drugs in two large Pacific Northwest metropolitan areas
We examined fentanyl use and outcomes among people who inject drugs (PWID) in the urban Pacific Northwest (PNW). We conducted secondary analysis of data fr
- 12 March 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Open AccessFentanyl use among people who inject drugs in two large Pacific Northwest metropolitan areas
We examined fentanyl use and outcomes among people who inject drugs (PWID) in the urban Pacific Northwest (PNW). We conducted secondary analysis of data fr
- 10 July 2025
- Published by Springer Nature in AIDS and Behavior
- Vol. 29 (12) , 3822-3829
Changes in the PrEP Care Cascade in People Who Inject Drugs in 2018 and 2022
HIV pre-exposure prophylaxis (PrEP) prevents HIV transmission. However, PrEP remains underutilized among people who inject drugs (PWID), even when clinically indicated. Here, we assess changes in PrEP awareness, access, and use in 2018 and 2022 and factors associated with PrEP awareness in 2022. We analyzed a sample of PWID not living with HIV with an indication for PrEP based on National HIV Behavioral Surveillance (NHBS) in Portland, Oregon during the 2018 and 2022 survey cycles. We compared PrEP awareness, access, and use in 2018 and 2022 with χ2. Using 2018 and 2022 data, we compared PrEP awareness between the two years with a Poisson regression. Using 2022 data, we assessed factors associated with PrEP awareness. Compared to 2018, PrEP awareness was higher in 2022 (33% vs 17%, p < 0.001, aPR = 1.24, 95% CI = 1.14–1.36). There were no significant differences in PrEP access or use between 2018 to 2022. In the 2022 sample, PrEP awareness was higher among those with Hispanic ethnicity compared to white, non-Hispanic PWID (aPR = 2.18, 95% CI = 1.21–3.90) and previous drug treatment (aPR = 1.79, 95% CI = 1.20–2.69). Although PrEP awareness was higher in 2022 than 2018, PrEP access and use were unchanged and remained rare. PrEP use among PWID remains insufficient to meet national Ending the HIV Epidemic goals.
- 10 July 2025
- Published by Springer Nature in AIDS and Behavior
- Vol. 29 (12) , 3822-3829
Changes in the PrEP Care Cascade in People Who Inject Drugs in 2018 and 2022
HIV pre-exposure prophylaxis (PrEP) prevents HIV transmission. However, PrEP remains underutilized among people who inject drugs (PWID), even when clinically indicated. Here, we assess changes in PrEP awareness, access, and use in 2018 and 2022 and factors associated with PrEP awareness in 2022. We analyzed a sample of PWID not living with HIV with an indication for PrEP based on National HIV Behavioral Surveillance (NHBS) in Portland, Oregon during the 2018 and 2022 survey cycles. We compared PrEP awareness, access, and use in 2018 and 2022 with χ2. Using 2018 and 2022 data, we compared PrEP awareness between the two years with a Poisson regression. Using 2022 data, we assessed factors associated with PrEP awareness. Compared to 2018, PrEP awareness was higher in 2022 (33% vs 17%, p < 0.001, aPR = 1.24, 95% CI = 1.14–1.36). There were no significant differences in PrEP access or use between 2018 to 2022. In the 2022 sample, PrEP awareness was higher among those with Hispanic ethnicity compared to white, non-Hispanic PWID (aPR = 2.18, 95% CI = 1.21–3.90) and previous drug treatment (aPR = 1.79, 95% CI = 1.20–2.69). Although PrEP awareness was higher in 2022 than 2018, PrEP access and use were unchanged and remained rare. PrEP use among PWID remains insufficient to meet national Ending the HIV Epidemic goals.
- 23 August 2023
- Published by Springer Nature in Archives of Sexual Behavior
- Vol. 52 (8) , 3313-3327
Type of Exchange Sex and Associated Behaviors and Outcomes Among Cisgender Men and Women at Increased Risk for HIV via Heterosexual Transmission in Six U.S. Metropolitan Areas
Exchange sex is associated with sexual risk behaviors and poor outcomes and different types may incur different levels of risk. We assessed risk profiles of different types of exchange sex among non-injecting cisgender men and women who participated in the 2019 National HIV Behavioral Surveillance project at six sites. Six percent of men and 19% of women reported exchange sex in the past year; most engaged in non-commercial exchange sex for drugs/money with smaller percentages reporting formal sex work or non-commercial exchange sex for goods or services other than drugs/money. Exchange sex was associated with sexual risk and prevention behaviors and psychosocial and sexual health outcomes and associations varied by type of exchange sex. Efforts to improve access to STI/HIV testing and PrEP may benefit from tailoring based on type of exchange sex. Findings indicate value in a broader definition of exchange sex with follow-up assessment of exchange sex typology.
- 23 August 2023
- Published by Springer Nature in Archives of Sexual Behavior
- Vol. 52 (8) , 3313-3327
Type of Exchange Sex and Associated Behaviors and Outcomes Among Cisgender Men and Women at Increased Risk for HIV via Heterosexual Transmission in Six U.S. Metropolitan Areas
Exchange sex is associated with sexual risk behaviors and poor outcomes and different types may incur different levels of risk. We assessed risk profiles of different types of exchange sex among non-injecting cisgender men and women who participated in the 2019 National HIV Behavioral Surveillance project at six sites. Six percent of men and 19% of women reported exchange sex in the past year; most engaged in non-commercial exchange sex for drugs/money with smaller percentages reporting formal sex work or non-commercial exchange sex for goods or services other than drugs/money. Exchange sex was associated with sexual risk and prevention behaviors and psychosocial and sexual health outcomes and associations varied by type of exchange sex. Efforts to improve access to STI/HIV testing and PrEP may benefit from tailoring based on type of exchange sex. Findings indicate value in a broader definition of exchange sex with follow-up assessment of exchange sex typology.
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108912
Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108912
Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study
- 1 January 2020
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 206, 107753
Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV
- 1 January 2020
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 206, 107753
Patterns of alcohol use and associated characteristics and HIV-related outcomes among a sample of African-American women living with HIV
- 20 October 2018
- Published by Springer Nature in AIDS and Behavior
- Vol. 23 (8) , 2025-2036
HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence
We used baseline data from a sample of African-American women living with HIV who were recruited to participate in a stigma-reduction intervention in Chicago and Birmingham (2013–2015) to (1) evaluate the relationship between HIV-related stigma and viral suppression, and (2) assess the role of depression and nonadherence to antiretroviral therapy (ART) as mediators. Data from women were included in this secondary analysis if they were on ART, had viral load data collected within 8-weeks of study entry and had complete covariate data. We used logistic regression to estimate the total effect of HIV-related stigma (14-item Stigma Scale for Chronic Illness) on viral suppression (< 200 copies/mL), and serial mediation analysis to estimate indirect effects mediated by depressive symptoms (8-item Patient Health Questionnaire) and ART nonadherence (number of days with missed doses). Among 100 women who met study inclusion criteria, 95% reported some level of HIV-related stigma. In adjusted models, higher levels of HIV-related stigma were associated with lower odds of being virally suppressed (AOR = 0.93, 95% CI = 0.89–0.98). In mediation analysis, indirect effects through depression and ART nonadherence were not significant. Findings suggest that HIV-related stigma is common among African-American women living with HIV, and those who experience higher levels of stigma are less likely to be virally suppressed. However, the mechanisms remain unclear.
- 20 October 2018
- Published by Springer Nature in AIDS and Behavior
- Vol. 23 (8) , 2025-2036
HIV-Related Stigma and Viral Suppression Among African-American Women: Exploring the Mediating Roles of Depression and ART Nonadherence
We used baseline data from a sample of African-American women living with HIV who were recruited to participate in a stigma-reduction intervention in Chicago and Birmingham (2013–2015) to (1) evaluate the relationship between HIV-related stigma and viral suppression, and (2) assess the role of depression and nonadherence to antiretroviral therapy (ART) as mediators. Data from women were included in this secondary analysis if they were on ART, had viral load data collected within 8-weeks of study entry and had complete covariate data. We used logistic regression to estimate the total effect of HIV-related stigma (14-item Stigma Scale for Chronic Illness) on viral suppression (< 200 copies/mL), and serial mediation analysis to estimate indirect effects mediated by depressive symptoms (8-item Patient Health Questionnaire) and ART nonadherence (number of days with missed doses). Among 100 women who met study inclusion criteria, 95% reported some level of HIV-related stigma. In adjusted models, higher levels of HIV-related stigma were associated with lower odds of being virally suppressed (AOR = 0.93, 95% CI = 0.89–0.98). In mediation analysis, indirect effects through depression and ART nonadherence were not significant. Findings suggest that HIV-related stigma is common among African-American women living with HIV, and those who experience higher levels of stigma are less likely to be virally suppressed. However, the mechanisms remain unclear.
- 1 January 2017
- Published by Project MUSE in Journal Of Health Care For The Poor and Underserved
- Vol. 28 (4) , 1254-1275
Evaluating the Impact of the Affordable Care Act on HIV Care, Outcomes, Prevention, and Disparities: A Critical Research Agenda
In the United States (U.S.), health care policy plays a critical role in ensuring adequate care for people living with HIV (PLWH), eliminating new HIV infections, and reducing health disparities. The 2010 Patient Protection and Affordable Care Act (ACA) was designed to make health care more accessible, of higher quality, and more affordable. Many provisions of the ACA are considered relevant to HIV care and prevention. Because PLWH have unique care needs and many groups at risk for infection are members of vulnerable populations, timely and comprehensive evaluation of the ACA in terms of HIV is critical. In this paper, we discuss components of the ACA relevant to HIV care and prevention, describe their anticipated and initial effects, and finally, outline a research agenda to inform future HIV programming and policy.
- 1 January 2017
- Published by Project MUSE in Journal Of Health Care For The Poor and Underserved
- Vol. 28 (4) , 1254-1275
Evaluating the Impact of the Affordable Care Act on HIV Care, Outcomes, Prevention, and Disparities: A Critical Research Agenda
In the United States (U.S.), health care policy plays a critical role in ensuring adequate care for people living with HIV (PLWH), eliminating new HIV infections, and reducing health disparities. The 2010 Patient Protection and Affordable Care Act (ACA) was designed to make health care more accessible, of higher quality, and more affordable. Many provisions of the ACA are considered relevant to HIV care and prevention. Because PLWH have unique care needs and many groups at risk for infection are members of vulnerable populations, timely and comprehensive evaluation of the ACA in terms of HIV is critical. In this paper, we discuss components of the ACA relevant to HIV care and prevention, describe their anticipated and initial effects, and finally, outline a research agenda to inform future HIV programming and policy.
- 24 April 2014
- Published by Wiley in World Journal of Surgery
- Vol. 38 (7) , 1614-1621
Disclosure of Adverse Events and Errors in Surgical Care: Challenges and Strategies for Improvement
The disclosure of adverse events to patients, including those caused by medical errors, is a critical part of patient‐centered healthcare and a fundamental component of patient safety and quality improvement. Disclosure benefits patients, providers, and healthcare institutions. However, the act of disclosure can be difficult for physicians. Surgeons struggle with disclosure in unique ways compared with other specialties, and disclosure in the surgical setting has specific challenges. The frequency of surgical adverse events along with a dysfunctional tort system, the team structure of surgical staff, and obstacles created inadvertently by existing surgical patient safety initiatives may contribute to an environment not conducive to disclosure. Fortunately, there are multiple strategies to address these barriers. Participation in communication and resolution programs, integration of Just Culture principles, surgical team disclosure planning, refinement of informed consent and morbidity and mortality processes, surgery‐specific professional standards, and understanding the complexities of disclosing other clinicians’ errors all have the potential to help surgeons provide patients with complete, satisfactory disclosures. Improvement in the regularity and quality of disclosures after surgical adverse events and errors will be key as the field of patient safety continues to advance.
- 24 April 2014
- Published by Wiley in World Journal of Surgery
- Vol. 38 (7) , 1614-1621
Disclosure of Adverse Events and Errors in Surgical Care: Challenges and Strategies for Improvement
The disclosure of adverse events to patients, including those caused by medical errors, is a critical part of patient‐centered healthcare and a fundamental component of patient safety and quality improvement. Disclosure benefits patients, providers, and healthcare institutions. However, the act of disclosure can be difficult for physicians. Surgeons struggle with disclosure in unique ways compared with other specialties, and disclosure in the surgical setting has specific challenges. The frequency of surgical adverse events along with a dysfunctional tort system, the team structure of surgical staff, and obstacles created inadvertently by existing surgical patient safety initiatives may contribute to an environment not conducive to disclosure. Fortunately, there are multiple strategies to address these barriers. Participation in communication and resolution programs, integration of Just Culture principles, surgical team disclosure planning, refinement of informed consent and morbidity and mortality processes, surgery‐specific professional standards, and understanding the complexities of disclosing other clinicians’ errors all have the potential to help surgeons provide patients with complete, satisfactory disclosures. Improvement in the regularity and quality of disclosures after surgical adverse events and errors will be key as the field of patient safety continues to advance.